| We represent the needs and concerns of our target population in joint discussions with regulatory authorities and industry stakeholders across a range of networks. | 婦科
> 婦科：其他 | 監管合作夥伴關係
> 與監管機構合作 | 100,000 | National | Sometimes | 115028466428 |
| We periodically prepare statements for submission as supporting documentation to drug reimbursement applications. | 未指定
> 未指定 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 10,000 | National | Sometimes | 114998339214 |
| We periodically prepare submissions to accompany medicine reimbursement applications. | 未指定
> 未指定 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 10,000 | National | Sometimes | 114998339214 |
| We provide formal submissions, and I have personally participated in consultation processes — for example, as part of the working group tasked with developing the pharmaceutical reimbursement system. | 骨骼
> 骨關節炎 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 10,000 | National | Regularly | 114998343058 |
| Patient organisation submissions to the authorities responsible for reimbursement decisions. | 癌症
> 癌症：乳腺癌 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 10,000 | National | Sometimes | 115043746918 |
| We are a patient organisation representing individuals living with osteoporosis, and we advocate for the patient perspective in all our interactions with regulatory authorities. | 骨骼
> 骨質疏鬆症 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 100,000 | National | Regularly | 114998337721 |
| We represent the needs and concerns of our target population in joint discussions with regulatory authorities and industry stakeholders across a range of networks. | 婦科
> 婦科：其他 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 100,000 | National | Sometimes | 115028466428 |
| We submit statements to regulatory channels from a patient perspective. | 癌症
> 癌症：大多數類型 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | Do not know | National | Regularly | 115040330840 |
| Occasional position statements and opinions, often issued jointly with another organisation or under the auspices of an umbrella body. | 風濕性
> 狼瘡 | 監管合作夥伴關係
> 與其他醫療倡導者 | 5,000 | National | Rarely | 115002845827 |
| Where there is a need to advocate or submit a formal statement, for example, we do so. | 一般健康
> 性健康：其他 | 影響政策及立法
> 影響醫療保健政策及立法 | 10,000 | National | Rarely | 115000148067 |
| We provide formal submissions, and I have personally participated in consultation processes — for example, as part of the working group tasked with developing the pharmaceutical reimbursement system. | 骨骼
> 骨關節炎 | 影響政策及立法
> 參與公眾聆訊及諮詢 | 10,000 | National | Regularly | 114998343058 |
| We submit consultation responses. | 骨骼
> 骨關節炎 | 影響政策及立法
> 參與公眾聆訊及諮詢 | 10,000 | National | Regularly | 114998343058 |
| Engagement with the city and the wellbeing services county to extend free pharmaceutical treatment to type 2 diabetes medicines. | 內分泌
> 糖尿病（1型及2型） | 定價及可負擔性倡議
> 倡導公平藥品定價 | 1,000 | Regional | Sometimes | 115006989892 |
| Medicine pricing, Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] reimbursement procedures, pharmacy services, and out-of-pocket medicine costs. | 殘疾
> 殘疾：大多數類型 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 1,000 | National | Regularly | 115007749998 |
| The price of obesity medicines. | 患者倡議
> 健康活動人士 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 1,000 | National | Sometimes | 115060416441 |
| For example, the Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] medicine credit pilot [a Finnish policy experiment designed to help low-income patients afford high-cost prescription medicines when they face a large out-of-pocket payment all at once], which commenced on 27 October and will run for three years. | 皮膚
> 牛皮癬 | 定價及可負擔性倡議
> 解決低收入及弱勢群體的費用負擔問題 | 10,000 | National | Regularly | 115000293575 |
| Medicine pricing, Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] reimbursement procedures, pharmacy services, and out-of-pocket medicine costs. | 殘疾
> 殘疾：大多數類型 | 定價及可負擔性倡議
> 解決低收入及弱勢群體的費用負擔問題 | 1,000 | National | Regularly | 115007749998 |
| Engagement with the city and the wellbeing services county to extend free pharmaceutical treatment to type 2 diabetes medicines. | 內分泌
> 糖尿病（1型及2型） | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 1,000 | Regional | Sometimes | 115006989892 |
| Patient organisation submissions to promote medicine reimbursement and access. | 神經肌肉
> 肌肉萎縮症 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 5,000 | National | Regularly | 115007479426 |
| Medicine pricing, Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] reimbursement procedures, pharmacy services, and out-of-pocket medicine costs. | 殘疾
> 殘疾：大多數類型 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 1,000 | National | Regularly | 115007749998 |
| For example, the Kela [Kansaneläkelaitos – Social Insurance Institution of Finland] medicine credit pilot [a Finnish policy experiment designed to help low-income patients afford high-cost prescription medicines when they face a large out-of-pocket payment all at once], which commenced on 27 October and will run for three years. | 皮膚
> 牛皮癬 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 10,000 | National | Regularly | 115000293575 |
| Engagement with the city and the wellbeing services county to extend free pharmaceutical treatment to type 2 diabetes medicines. | 內分泌
> 糖尿病（1型及2型） | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 1,000 | Regional | Sometimes | 115006989892 |
| Patient organisation submissions to promote medicine reimbursement and access. | 神經肌肉
> 肌肉萎縮症 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 5,000 | National | Regularly | 115007479426 |
| We are a patient organisation representing individuals living with osteoporosis, and we advocate for the patient perspective in all our interactions with regulatory authorities. | 骨骼
> 骨質疏鬆症 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | 100,000 | National | Regularly | 114998337721 |
| We submit statements to regulatory channels from a patient perspective. | 癌症
> 癌症：大多數類型 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | Do not know | National | Regularly | 115040330840 |
| ... We are represented on Fimea's [Lääkealan turvallisuus- ja kehittämiskeskus – Finnish Medicines Agency] patient advisory board. | 未指定
> 未指定 | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 10,000 | National | Sometimes | 114998339214 |
互動
行動與倡議
8 提及
